- Home
- INDO vs INTS Comparison
INDO vs INTS Comparison
Compare INDO & INTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INDO
- INTS
- Stock Information
- Founded
- INDO 2018
- INTS 2012
- Country
- INDO Indonesia
- INTS United States
- Employees
- INDO N/A
- INTS N/A
- Industry
- INDO Oil & Gas Production
- INTS Biotechnology: Pharmaceutical Preparations
- Sector
- INDO Energy
- INTS Health Care
- Exchange
- INDO Nasdaq
- INTS Nasdaq
- Market Cap
- INDO 40.1M
- INTS 35.3M
- IPO Year
- INDO 2019
- INTS 2023
- Fundamental
- Price
- INDO $2.60
- INTS $2.33
- Analyst Decision
- INDO
- INTS Strong Buy
- Analyst Count
- INDO 0
- INTS 3
- Target Price
- INDO N/A
- INTS $8.50
- AVG Volume (30 Days)
- INDO 152.0K
- INTS 18.1K
- Earning Date
- INDO 04-25-2025
- INTS 03-21-2025
- Dividend Yield
- INDO N/A
- INTS N/A
- EPS Growth
- INDO N/A
- INTS N/A
- EPS
- INDO N/A
- INTS N/A
- Revenue
- INDO $3,127,587.00
- INTS N/A
- Revenue This Year
- INDO N/A
- INTS N/A
- Revenue Next Year
- INDO N/A
- INTS N/A
- P/E Ratio
- INDO N/A
- INTS N/A
- Revenue Growth
- INDO N/A
- INTS N/A
- 52 Week Low
- INDO $2.05
- INTS $1.50
- 52 Week High
- INDO $6.65
- INTS $5.78
- Technical
- Relative Strength Index (RSI)
- INDO 43.45
- INTS 53.36
- Support Level
- INDO $2.50
- INTS $2.17
- Resistance Level
- INDO $2.72
- INTS $2.43
- Average True Range (ATR)
- INDO 0.14
- INTS 0.20
- MACD
- INDO -0.01
- INTS 0.01
- Stochastic Oscillator
- INDO 29.41
- INTS 73.08
Stock Price Comparison Chart: INDO vs INTS
About INDO Indonesia Energy Corporation Limited
Indonesia Energy Corp Ltd is an oil and gas exploration and production company focused on Indonesia. Its portfolio consists of Kruh Block and Citarum Block. The company generates its revenue from oil and gas sales.
About INTS Intensity Therapeutics Inc. Common stock
Intensity Therapeutics Inc is a clinical-stage biotechnology company pioneering a new immune-based approach to treat solid tumor cancers. The company leverages its DfuseRxtechnology platform to create new, proprietary drug formulations that, following direct injection, rapidly disperse throughout a tumor and diffuse therapeutic agents into cancer cells. Intensity's product candidates have the potential to induce an adaptive systemic immune response that not only attacks the injected tumor, but also non-injected tumors. Their pipeline is focused on realizing the full potential of INT230-6 in metastatic and local disease settings to help cancer patients with major unmet medical need.